COMMENTARY

• Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
  July 4, 2011

• Era of Competition Dawns in Market for AD Treatments
  June 27, 2011

• Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
  June 20, 2011

• Return to Full-bore Growth Strategy Risky for Taiyo Pharm
  June 13, 2011

• Why the Same Mistake Repeated? -MSD's Promotion Code Violations
  June 6, 2011

• GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
  June 6, 2011

• Effects of Changes to Accelerate Approval to Be Seen from November
  May 30, 2011

• Japan's Most Admired Pharma Companies in 2010
  April 4, 2011

• Will New Disclosure GL Promote Industry-Academia Alliances?
  March 28, 2011

• Use of Generics by Welfare Recipients
  March 7, 2011

• Wholesalers' Profits Drop Sharply Putting Premium for New Drug Development in Peril
  February 21, 2011

• Safety Measures Based on Common Medical Knowledge Questioned by Court: Iressa Affair
  February 21, 2011

• Recent Topics in Promising Anticancer Therapeutics
  January 17, 2011

• Development Race for Oral Anticoagulants Entering Final Stretch
  October 11, 2010

• How to Eliminate Concerns about Safety of Liovel
  October 4, 2010

• Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
  September 20, 2010

• Big Pharma Losing Flagships within a Few Years and Shifting Paradigm
  September 13, 2010

• Prior Assessment System Is One Step Forward to Quicker NDA Review
  August 2, 2010

• Industry Needs to Form Consensus on Premium with Med. Institutions
  July 26, 2010

• Japan Should Promote Personalized Cancer Treatment
  July 26, 2010

ページ